Disc Medicine (NASDAQ:IRON) versus Bolt Biotherapeutics (NASDAQ:BOLT) Head to Head Analysis

Bolt Biotherapeutics (NASDAQ:BOLT) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Earnings and Valuation

This table compares Bolt Biotherapeutics and Disc Medicine”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.70 million	1.11	-$33.38 million	($16.33)	-0.27
Disc Medicine	N/A	N/A	-$212.18 million	($6.62)	-11.23

Bolt Biotherapeutics has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bolt Biotherapeutics and Disc Medicine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-455.15%	-100.89%	-48.23%
Disc Medicine	N/A	-36.94%	-33.88%

Analyst Recommendations

This is a summary of current recommendations and price targets for Bolt Biotherapeutics and Disc Medicine, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1	1	3	0	2.40
Disc Medicine	1	1	9	0	2.73

Bolt Biotherapeutics presently has a consensus price target of $34.67, indicating a potential upside of 676.41%. Disc Medicine has a consensus price target of $104.44, indicating a potential upside of 40.44%. Given Bolt Biotherapeutics’ higher probable upside, equities analysts clearly believe Bolt Biotherapeutics is more favorable than Disc Medicine.

Institutional & Insider Ownership

86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 9.4% of Bolt Biotherapeutics shares are held by insiders. Comparatively, 3.8% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Bolt Biotherapeutics has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Disc Medicine has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

Summary

Bolt Biotherapeutics beats Disc Medicine on 7 of the 13 factors compared between the two stocks.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

About Disc Medicine

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company’s preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.